+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Identification of metabolic pathways of brain angiotensin II and angiotensin III: predominant role of angiotensin III in the control of vasopressin secretion



Identification of metabolic pathways of brain angiotensin II and angiotensin III: predominant role of angiotensin III in the control of vasopressin secretion



Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales 192(4): 607-618



Angiotensin (Ang) II and AngIII are two peptide effectors of the brain renin-angiotensin system that participate in the control of blood pressure and increase water consumption and vasopressin release. In an attempt to delineate the respective roles of these peptides in the regulation of vasopressin secretion, their metabolic pathways and their effects on vasopressin release were identified in vivo. For this purpose, we used recently developed selective inhibitors of aminopeptidase A (APA) and aminopeptidase N (APN), two enzymes that are believed to be responsible for the N-terminal cleavage of AngII and AngIII, respectively. Mice received [3H]AngII intracerebroventricularly (i.c.v.) in the presence or absence of the APA inhibitor, EC33 ((S)-3-amino-4-mercapto-butylsulfonate de sodium) or the APN inhibitor, EC27 ((S)-2-amino-pentan-1,5-dithiol). [3H]AngII and [3H]AngIII levels were evaluated from hypothalamus homogenates by HPLC. EC33 increased the half-life of [3H]AngII 2.6-fold and completely blocked the formation of [3H]AngIII, whereas EC27 increased the half-life of [3H]AngIII 2.3-fold. In addition, the effects of EC33 and EC27 on Ang- induced vasopressin release were studied in mice. AngII was injected i.c.v. in the presence or absence of EC33, and plasma vasopressin levels were estimated by RIA. While vasopressin levels were increased 2-fold by AngII, EC33 inhibited AngII-induced vasopressin release in a dose-dependent manner. In contrast, EC27 injected alone increased in a dose-dependent manner vasopressin levels. The EC27-induced vasopressin release was completely blocked by the coadministration of the Ang receptor antagonist (Sar1-Ala8) AngII. These results demonstrate for the first time that i) APA and APN are involved in vivo in the metabolism of brain AngII and AngIII, respectively, and that ii) the action of AngII on vasopressin release depends upon the prior conversion of AngII to AngIII. This shows that AngIII behaves as one of the main effector peptides of the brain renin-angiotensin system in the control of vasopressin release.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 046316096

Download citation: RISBibTeXText

PMID: 9842467


Related references

Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: Predominant role of angiotensin III in the control of vasopressin release. Proceedings of the National Academy of Sciences of the United States of America 93(21): 11968-11973, 1996

The renin-angiotensin system and vascular function. The role of angiotensin II, angiotensin-converting enzyme, and alternative conversion of angiotensin I. Heart and Vessels Suppl 12: 119-124, 1997

Metabolic pathways and respective roles of brain angiotensin II and III in vasopressin release. Fundamental & Clinical Pharmacology 11(SUPPL 1): 64S, 1997

Localization of angiotensin-converting enzyme, angiotensin II, angiotensin II receptor subtypes, and vasopressin in the mouse hypothalamus. Brain Research. 757(2): 218-227, 1997

Respective roles of angiotensin II and angiotensin III in the central regulation of vasopressin secretion. Society for Neuroscience Abstracts 21(1-3):, 1995

Effect of angiotensin-converting enzyme inhibitor (SQ 20881) on the plasma concentration of angiotensin I, angiotensin II, and arginine vasopressin in the dog during hemorrhagic shock. Circulation Research 41(3): 301-308, 1977

A comparison between the effects of angiotensin ii and angiotensin iii injected into the 3rd cerebral ventricle on vasopressin secretion in conscious rats. Folia Endocrinologica Japonica 55(10): 1286-1295, 1979

A comparison between the effects of angiotensin II and angiotensin III injected into the third cerebral ventricle on vasopressin secretion in conscious rats. Nihon Naibunpi Gakkai Zasshi 55(10): 1286-1295, 1979

Interactions between the brain renin-angiotensin system and brain prostanoids in the control of vasopressin secretion. Experimental Brain Research 83(1): 131-136, 1990

The role of angiotensin, AT1 and AT2 receptors in the pressor, drinking and vasopressin responses to central angiotensin. Brain Research 586(2): 289-294, 1992

Aminopeptidase A, generating one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, plays a key role in the central control of blood pressure. Biochemical Society Transactions 28(3): A60, 2000

Aminopeptidase A, generating one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, plays a key role in central control of blood pressure. Proceedings of the Western Pharmacology Society 46: 39-44, 2004

Aminopeptidase A, which generates one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, has a key role in central control of arterial blood pressure. Biochemical Society Transactions 28(4): 435-440, 2000

Aminopeptidase A, which generates one of the main effector peptides of the brain renin-angiotensin system, angiotensin Iii, has a key role in central control of arterial blood pressure. Biochemical Society Transactions 28(4): 435-440, 2000

Role of the renin-angiotensin system in the control of vasopressin secretion in conscious dogs. Circulation Research 58(6): 829-838, 1986